Overslaan en naar de inhoud gaan

Pharming Group N.V. announces today the expansion of its rare disease pipeline with plans to develop leniolisib for additional primary immunodeficiencies (PIDs) beyond activated phosphoinositide 3-kinase delta syndrome (APDS).

Download the press release below to learn more.

"...unbalanced PI3Kẟ signaling in lymphocytes is a key signature of immune dysregulation among PID patients who develop lymphoproliferative and autoimmune disease."

- Dr. Jocelyn Farmer, MD/PhD, Director, Clinical Immunodeficiency Program, Beth Israel Lahey Health
Cookies: Deze website maakt gebruik van cookies. Bekijk de cookie instellingen pagina voor meer informatie Accepteren Weigeren